Navigation
Home
Advocating for Access
Background
Letters for Access
Press Releases For Access
Simplified Community Materials
Simplified Community Materials
Understanding your HCV infection
Community Led Reports
Country Information
Indonesia
India
Vietnam
Generic DAAs Pricing
Resources
Guidelines
Key Research Publication
Other Important Documents and Reports
News
Gallery
Photos
Video
Stories
Pricing and availability of generic Indian Ledipasvir and Sofosbuvir co-formulation as on 26 April 2016
Pricing and availability of generic Indian Ledipasvir and Sofosbuvir co-formulation as on 26 April 2016
Download PDF
May 3, 2016
/
News
Share
the Post
Related
Posts
Asia-Pacific Aids Groups Express Deep Dismay At Conclusion Of Secretly Negotiated Trans-Pacific Partnership Agreement That Threatens Future Access To Affordable Generic Medicines And Sustainable Development Goals
Patent Situation of The Key Product For Treatment of Hepatitis C: SOFOSBUVIR – WHO working paper, updated 2015
The use of generic DAAs for hepatitis C treatment, Freeman et al 2016
Patent Situation of The Key Product for Treatment of Hepatitis C: DACLASTAVIR – WHO working paper, revised version, Oct 2014
Pricing of Indian generic sofosbuvir, 30th Jan,2016
Progress report on access to hepatitis C treatment, WHO March 2018
IAC a community group in Indonesia demanding national food and drugs authority to expedite registration process of DAA medicines in Indonesia
Updated WHO screening, care and treatment of persons with hepatitis C infection_ April 2016.
